Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: Adults and paediatric patients with moderately to severely active CD or UC who have had an...), Ulcerative Colitis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Non-Infectious Uveitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
US
  • Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate.
  • Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Product first approved 2002Outside this platform's coverageFDA label
JP
  • Treatment of rheumatoid arthritis (for use only when conventional therapies are not sufficiently effective)
Product first approved 2008PMDA
CA
  • Humira is indicated for: Rheumatoid Arthritis  reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira can be used alone or in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs). When used as first-line treatment in recently diagnosed patients who have not been previously treated with methotrexate, Humira should be given in combination with methotrexate....
Product first approved 2004Health Canada
UK
  • Moderate to severely active Crohn's disease and ulcerative colitis in adults and paediatric patients
Product first approved 2003medicines.org.uk
EU
  • Please refer to the product information document.
Product first approved 2003EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (115)
Crohn's Disease
NCT02332356 · Tokyo Medical and Dental University
2014-09 – 2024-03 · Crohn Disease
What this study did
NCT01986127 · Sara Varea
2014-02-14 – 2018-06-30 · Crohn's Disease
What this study did
NCT01629628 · Tel-Aviv Sourasky Medical Center
2012-07 – 2016-07 · Crohn Disease
What this study did
NCT01674413 · Peter Higgins
2013-10 – 2016-03 · Crohn's Disease
What this study did
NCT01562951 · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012-10 – 2014-03 · Crohn's Disease, Mucosal Inflammation
What this study did
NCT00736983 · Foundation for Liver Research
2008-09 – 2011-12 · Crohn's Disease With Perianal Fistulas
What this study did
NCT00077779 · Abbott
started 2003-07 · Crohn's Disease
What this study did
Hidradenitis Suppurativa
NCT02904902 · AbbVie
2016-09-06 – 2019-05-30 · Hidradenitis Suppurativa
What this study did
NCT01635764 · AbbVie (prior sponsor, Abbott)
2012-04 – 2016-08 · Hidradenitis Suppurativa
What this study did
NCT01468233 · AbbVie (prior sponsor, Abbott)
2011-11 – 2014-04 · Hidradenitis Suppurativa (HS)
What this study did
Non-Infectious Uveitis
NCT06258915 · Assistance Publique - Hôpitaux de Paris
2024-03-01 – 2027-11-01 · Non Infectious Uveitis
What this study did
Psoriasis
NCT05495568 · Celltrion
2022-11-07 – 2024-02-05 · Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT05637515 · Biocon Biologics Inc.
2022-11-21 – 2023-09-19 · Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
What this study did
NCT04453137 · Alvotech Swiss AG
2020-06-30 – 2021-11-16 · Plaque Psoriasis
What this study did
NCT03849404 · Alvotech Swiss AG
2019-02-20 – 2020-07-20 · Plaque Psoriasis
What this study did
NCT02533375 · AbbVie
2015-09-28 – 2017-07-20 · Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese
What this study did
NCT02581345 · Momenta Pharmaceuticals, Inc.
2015-09 – 2017-04-04 · Chronic Plaque Psoriasis, Psoriasis
What this study did
NCT02196701 · AbbVie
2014-08-05 – 2017-03-17 · Psoriasis
What this study did
NCT02016482 · AbbVie
2014-01 – 2016-04 · Nail Psoriasis, Plaque Psoriasis
What this study did
NCT01251614 · AbbVie (prior sponsor, Abbott)
2010-12 – 2015-02 · Plaque Psoriasis
What this study did
NCT01646073 · AbbVie (prior sponsor, Abbott)
2012-08 – 2013-12 · Plaque Psoriasis
What this study did
NCT00566722 · Abbott
2008-01 – 2009-04 · Psoriasis
What this study did
NCT00927069 · Innovaderm Research Inc.
2007-03 – 2008-12 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT00195689 · Abbott
started 2003-08 · Psoriatic Arthritis
What this study did
NCT00235885 · Abbott
started 2005-07 · Psoriatic Arthritis
What this study did
Phase 2/3 (13)
Crohn's Disease
Psoriasis
NCT03217734 · Jeffrey J Crowley MD
2017-04-10 – 2018-12-31 · Psoriasis
What this study did
NCT00647400 · Abbott
2006-04 – 2010-04 · Psoriasis
What this study did
NCT00338754 · Abbott
started 2005-11 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT05172817 · Institute for Developing Science and Health Initiatives, Bangladesh
2021-06-02 – 2022-10-30 · Pharmacokinetics, Safety, Efficacy, Rheumatoid Arthritis
What this study did
NCT00538902 · Abbott
2007-08 – 2009-12 · Rheumatoid Arthritis
What this study did
NCT00647491 · Abbott
2004-02 – 2005-08 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT05299242 · University of Oxford
2022-07-21 – 2023-06-12 · Frozen Shoulder
What this study did
NCT01385826 · Assistance Publique - Hôpitaux de Paris
2011-06-29 – 2015-08-27 · Uveitis, Juvenile Arthritis
What this study did
NCT00348153 · Heidelberg University
2006-08 – 2013-03 · Uveitis
What this study did
NCT00235105 · Charite University, Berlin, Germany
2005-03 – 2007-06 · Ankylosing Spondylitis
What this study did
Phase 2 (58)
Crohn's Disease
NCT04655807 · Janssen Research & Development, LLC
2021-03-03 – 2023-09-04 · Crohn Disease
What this study did
NCT00055523 · Abbott
started 2002-04 · Crohn's Disease
What this study did
Hidradenitis Suppurativa
NCT02643654 · Evangelos J. Giamarellos-Bourboulis, M.D.
2015-12 – 2017-02 · Hidradenitis Suppurativa
What this study did
NCT00918255 · Abbott
2009-04 – 2010-11 · Hidradenitis Suppurativa
What this study did
NCT00827996 · Florida Academic Dermatology Centers
2007-02 – 2008-08 · Hidradenitis Suppurativa
What this study did
Non-Infectious Uveitis
NCT05155592 · Dan Liang
2021-01-01 – 2023-04-01 · Uveitis, Adalimumab
What this study did
NCT02706704 · American University of Beirut Medical Center
2016-02 – 2022-01 · Uveitis, Non-Infectious Uveitis
What this study did
NCT00525902 · Oregon Health and Science University
2008-01 – 2010-09 · Uveitis
What this study did
Psoriasis
NCT01872546 · Poitiers University Hospital
2013-01 – 2013-09 · Chronic Plaque Psoriasis
What this study did
NCT00645905 · Abbott
2003-06 – 2005-03 · Psoriasis
What this study did
NCT00645892 · Abbott
2003-11 – 2004-09 · Psoriasis
What this study did
NCT00646191 · Abbott
2003-03 – 2004-06 · Psoriasis
What this study did
NCT00645814 · Abbott
2003-03 – 2003-09 · Psoriasis
What this study did
Psoriatic Arthritis
Rheumatoid Arthritis
NCT03938701 · University Medical Center Groningen
2024-08-06 – 2026-08-01 · IBD, Rheumatoid Arthritis
What this study did
NCT02393378 · Takeda
2015-04-08 – 2016-11-16 · Rheumatoid Arthritis
What this study did
NCT02565810 · Samsung Bioepis Co., Ltd.
2015-09 – 2016-03 · Rheumatoid Arthritis
What this study did
NCT01752855 · AbbVie (prior sponsor, Abbott)
2012-12 – 2013-10 · Rheumatoid Arthritis
What this study did
NCT01712178 · AbbVie (prior sponsor, Abbott)
2012-06 – 2013-05 · Rheumatoid Arthritis
What this study did
NCT01502423 · AbbVie (prior sponsor, Abbott)
2012-01 – 2012-11 · Rheumatoid Arthritis
What this study did
NCT01561313 · AbbVie (prior sponsor, Abbott)
2012-03 – 2012-11 · Rheumatoid Arthritis
What this study did
NCT01163617 · AbbVie (prior sponsor, Abbott)
2010-05 – 2010-11 · Rheumatoid Arthritis
What this study did
NCT00235833 · Abbott
2003-06 – 2004-10 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05372939 · Applied Molecular Transport
2021-02-05 – 2022-07-13 · Ulcerative Colitis
What this study did
NCT01716039 · Alimentiv Inc.
2013-06 – 2016-07-18 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07845604 · Daniel Moriarity
2026-11 – 2031-09 · Major Depressive Disorder (MDD)
What this study did
NCT07268534 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Folliculitis Decalvans (FD)
What this study did
NCT06037811 · Tom Appleton
2024-04-15 – 2028-12 · Inflammatory Arthritis, Immune-related Adverse Event
What this study did
NCT06849908 · Peking Union Medical College Hospital
2024-11-08 – 2028-06-30 · Behcet Syndrome, Intestinal Type
What this study did
NCT06062875 · Endeavor Health
2024-01-24 – 2028-06-01 · Benign Prostatic Hyperplasia (BPH)
What this study did
NCT05590455 · ANRS, Emerging Infectious Diseases
2023-04-11 – 2027-12 · Tuberculous Meningitis, HIV I Infection
What this study did
NCT06941376 · University of Pennsylvania
2025-11-11 – 2027-12 · Relapsing Polychondritis
What this study did
NCT05874505 · Assistance Publique - Hôpitaux de Paris
2023-07 – 2027-07 · Behcet's Uveitis
What this study did
NCT03651518 · Assistance Publique - Hôpitaux de Paris
2020-10-20 – 2025-11-20 · Inflammatory Disease, Autoimmune Diseases
What this study did
NCT04588818 · Sun Yat-sen University
2020-02-01 – 2023-12-31 · Uveitis
What this study did
NCT04009668 · University of Michigan
2019-10-02 – 2023-10-03 · FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
What this study did
NCT02471118 · CARE ARTHRITIS LTD.
2015-03 – 2021-03 · Osteoarthritis, Knee
What this study did
NCT03180957 · University of Oxford
2016-03-02 – 2020-12 · Dupuytren's Disease
What this study did
NCT00690911 · Wake Forest University
— · Sarcoidosis
What this study did
NCT02113904 · Assistance Publique - Hôpitaux de Paris
2014-01-27 – 2017-09-21 · Netherton Syndrome
What this study did
NCT04154852 · University of Leeds
2011-06 – 2017-01-16 · Oligoarthritis
What this study did
NCT00814255 · NYU Langone Health
2008-12 – 2014-02 · Focal Segmental Glomerulosclerosis
What this study did
NCT00274352 · Pariser, Robert J., M.D.
2006-09 – 2012-02 · Sarcoidosis
What this study did
NCT01136252 · Hospital Universitari Vall d'Hebron Research Institute
2010-05 – 2011-10 · Age-Related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT00514982 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-08-07 – 2011-03-08 · Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
What this study did
Phase 1/2 (11)
Crohn's Disease
NCT01275508 · University of Erlangen-Nürnberg Medical School
2011-01 – 2012-04 · Crohn's Disease
What this study did
Psoriasis
NCT01704599 · Wayne State University
2009-01 – 2014-05 · Psoriasis
What this study did
Ulcerative Colitis
NCT07258641 · University Medical Center Groningen
2026-01-15 – 2028-04-01 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
NCT06117423 · University Medical Center Groningen
2024-03 – 2025-06 · Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT07061574 · City of Hope Medical Center
2026-03-10 – 2031-04-15 · Type 1 Diabetes, New Onset
What this study did
NCT07348588 · Centro de Pesquisa Rubens Siqueira
2025-07-10 – 2027-08-01 · Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)
What this study did
NCT03153319 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2017-06-05 – 2027-02 · Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
What this study did
NCT02586831 · Camillo Ricordi and Jay Skyler
2024-06-01 – 2024-06-01 · Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
What this study did
NCT03607903 · Centre for Human Drug Research, Netherlands
2018-07-11 – 2018-10-30 · Pain, Injection Site
What this study did
NCT02437253 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2015-05 – 2016-07 · Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
What this study did
NCT00686439 · University of Alberta
2008-06 – 2010-11 · Osteoarthritis
What this study did
Phase 1 (18)
Rheumatoid Arthritis
NCT00650156 · AbbVie
2007-06 – 2007-10 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT06742606 · Ain Shams University
2025-01-15 – 2026-12-13 · Effect of Drug
What this study did
NCT00421642 · Mayo Clinic
2006-10 – 2008-04 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06926478 · Massachusetts Eye and Ear Infirmary
2026-10-01 – 2028-06-01 · Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
What this study did
NCT06291948 · Laboratorios Richmond S.A.C.I.F.
2022-08-01 – 2023-10-20 · Pharmacokinetics, Safety Issues
What this study did
NCT05884242 · Janssen Research & Development, LLC
2023-05-22 – 2023-08-07 · Healthy
What this study did
NCT04551352 · Hoffmann-La Roche
2020-10-28 – 2022-07-28 · Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
What this study did
NCT04514796 · Samsung Bioepis Co., Ltd.
2020-08-13 – 2021-05-15 · Healthy
What this study did
NCT03849313 · Alvotech Swiss AG
2019-03-20 – 2020-02-17 · Healthy Volunteers
What this study did
NCT03983876 · Alvotech Swiss AG
2019-07-01 – 2019-12-03 · Phase 1
What this study did
NCT03273192 · Cinnagen
2016-10-22 – 2017-08-06 · Bioequivalence, Phase 1
What this study did
NCT02516774 · Gustave Roussy, Cancer Campus, Grand Paris
2014-12 – 2015-12 · Anaplastic Thyroid Cancers
What this study did
NCT02237729 · Pfizer
2014-09 – 2015-03 · Healthy Subjects
What this study did
NCT02144714 · Samsung Bioepis Co., Ltd.
2014-05 – 2014-09 · Healthy
What this study did
NCT00855608 · Rafic Hariri University Hospital
2009-03 – 2013-03 · Uveitis, Diabetic Retinopathy, Choroidal Neovascularization
What this study did
NCT02252809 · Brugmann University Hospital
2008-11 – 2009-07 · Innate Immunity
What this study did
NCT00193648 · Northwell Health
2005-07 – 2007-10 · Focal Glomerulosclerosis
What this study did
Phase 4 (103)
Crohn's Disease
NCT07510191 · Sixth Affiliated Hospital, Sun Yat-sen University
2026-03-01 – 2029-12-31 · Crohn Disease (CD)
What this study did
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did
NCT06045754 · Takeda
2024-04-18 – 2027-06-28 · Crohn's Disease
What this study did
NCT03917303 · Maastricht University Medical Center
2019-12-23 – 2026-09 · Crohn Disease, Inflammatory Bowel Diseases
What this study did
NCT03306446 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2015-03-17 – 2025-03 · CD
What this study did
NCT03172377 · Radboud University Medical Center
2017-05-03 – 2022-10 · Crohn Disease in Remission, Crohn Disease
What this study did
NCT02764762 · Takeda
2017-04-18 – 2022-07-05 · Crohn Disease
What this study did
NCT02852694 · PIBD-Net
2017-02-28 – 2021-06-14 · Crohn's Disease
What this study did
NCT02256462 · Schneider Children's Medical Center, Israel
2015-05-01 – 2019-01-31 · Crohn's Disease
What this study did
NCT02148718 · AbbVie
2014-06 – 2017-01 · Moderate to Severe Crohn's Disease
What this study did
NCT01556672 · Innovaderm Research Inc.
2012-04 – 2016-04 · Plaque Psoriasis, Crohn's Disease
What this study did
NCT00972218 · University of Alberta
2009-07 – 2010-01 · Spondyloarthritis, Crohn's Disease
What this study did
Hidradenitis Suppurativa
NCT04132388 · Wake Forest University Health Sciences
2020-08-20 – 2022-09-07 · Hidradenitis Suppurativa
What this study did
NCT02808975 · AbbVie
2016-07-18 – 2019-10-16 · Hidradenitis Suppurativa (HS)
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT07529925 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-05 – 2028-05 · Severe Plaque Psoriasis in Chinese Children
What this study did
NCT05510063 · Samsung Bioepis Co., Ltd.
2022-08-04 – 2023-05-04 · Plaque Psoriasis
What this study did
NCT05683054 · University Hospital, Ghent
2020-08-11 – 2022-08-22 · Psoriasis
What this study did
NCT04028713 · University Hospital, Ghent
2021-02-16 – 2022-03-22 · Psoriasis Vulgaris
What this study did
NCT00932113 · Tufts Medical Center
2009-06 – 2017-05-01 · Psoriasis
What this study did
NCT01553058 · University of Pennsylvania
2012-07 – 2016-10-27 · Psoriasis, Cardiovascular Disease
What this study did
NCT01866592 · University of Pennsylvania
2013-04 – 2016-10-27 · Psoriasis, Cardiovascular Disease
What this study did
NCT01722214 · Innovaderm Research Inc.
2012-11 – 2016-01 · Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
What this study did
NCT01088165 · Medical University of Vienna
2010-05 – 2014-05 · Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2
What this study did
NCT01644396 · AbbVie (prior sponsor, Abbott)
2012-05 – 2013-09 · Moderate to Severe Plaque Psoriasis
What this study did
NCT01265823 · AbbVie (prior sponsor, Abbott)
2010-10 – 2012-02 · Psoriasis
What this study did
NCT01181570 · Innovaderm Research Inc.
2010-09 – 2011-09 · Psoriasis, Sleep Apnea, Obstructive
What this study did
NCT00940862 · Innovaderm Research Inc.
2009-07 – 2011-08 · Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
What this study did
NCT01237262 · University of Padova
2010-11 – 2010-11 · Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
What this study did
NCT00735787 · Abbott
2008-08 – 2009-09 · Psoriasis
What this study did
Psoriatic Arthritis
NCT03739853 · University of Oxford
2019-05-14 – 2024-10-31 · Psoriatic Arthritis
What this study did
NCT01465438 · Glostrup University Hospital, Copenhagen
2006-11 – 2011-06 · Psoriatic Arthritis
What this study did
NCT00133315 · Hvidovre University Hospital
2004-09 – 2007-04 · Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05626348 · Qilu Hospital of Shandong University
2021-12-22 – 2026-12-31 · Arthritis, Rheumatoid
What this study did
NCT04194827 · Reade Rheumatology Research Institute
2020-03-01 – 2024-12 · Rheumatoid Arthritis
What this study did
NCT01793519 · Georgetown University
2013-01 – 2024-08-30 · Rheumatoid Arthritis
What this study did
NCT04251741 · Reade Rheumatology Research Institute
2020-07-31 – 2024-05-01 · Rheumatoid Arthritis
What this study did
NCT04222920 · Reade Rheumatology Research Institute
2020-03-01 – 2023-09-11 · Rheumatoid Arthritis
What this study did
NCT03619876 · Columbia University
2019-07-10 – 2021-09-15 · Rheumatoid Arthritis, Myocardial Inflammation
What this study did
NCT03505008 · Keio University
2018-04-18 – 2021-05-11 · Rheumatoid Arthritis
What this study did
NCT02374021 · Brigham and Women's Hospital
2016-07 – 2021-05 · Arthritis, Rheumatoid
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT03737708 · Astellas Pharma Korea, Inc.
2019-02-13 – 2020-06-16 · Rheumatoid Arthritis (RA)
What this study did
NCT02878161 · Fen Li
2016-01 – 2019-12 · Rheumatoid Arthritis
What this study did
NCT02035800 · Université de Sherbrooke
2013-05 – 2019-12 · RheumatoId Arthritis
What this study did
NCT02056184 · University of Leeds
2013-12 – 2019-07 · Rheumatoid Arthritis, Targeted Ultrasound
What this study did
Early phase / not applicable (29)
Crohn's Disease
NCT03261102 · waqqas.afif
2017-01-17 – 2025-06-01 · Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases
What this study did
NCT04200547 · University Hospital, Montpellier
2020-01-29 – 2024-06-29 · Crohn Disease
What this study did
NCT02539849 · Hospital Universitari Vall d'Hebron Research Institute
2014-12 – 2017-12-19 · Crohn Disease
What this study did
NCT01144156 · Rabin Medical Center
— · Crohn's Disease
What this study did
Psoriasis
NCT07128472 · South Valley University
2025-08-01 – 2026-02-01 · Psoriasis
What this study did
NCT05889338 · Sohag University
2023-06 – 2024-01 · Psoriasi
What this study did
NCT03389984 · Poitiers University Hospital
2017-11-14 – 2020-06-18 · Psoriasis Vulgaris
What this study did
NCT01320293 · University of North Carolina, Chapel Hill
2011-03 – 2015-03 · Psoriasis
What this study did
NCT00638469 · Medical University of Graz
2008-03 – 2014-12 · Psoriasis
What this study did
NCT01657513 · University Hospital, Gentofte, Copenhagen
2012-06 – 2013-07 · Psoriasis
What this study did
NCT01435265 · Wake Forest University Health Sciences
2010-01 – 2012-04 · Psoriasis
What this study did
NCT00638261 · Medical University of Graz
2008-03 – 2011-08 · Psoriasis
What this study did
Psoriatic Arthritis
NCT07398651 · Tanta University
2026-12-30 – 2026-12-30 · Psoriatic Arthritis, Ultrasound Assessment, TNF
What this study did
NCT06729463 · South Valley University
2024-12-01 – 2025-03-30 · Psoriasis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05090124 · NHS Greater Glasgow and Clyde
2022-11-04 – 2024-11-29 · Rheumatoid Arthritis
What this study did
NCT05460390 · Boston Medical Center
2022-10-26 – 2024-06-30 · Rheumatoid Arthritis
What this study did
NCT03110094 · Rennes University Hospital
2017-03-13 – 2020-01-13 · Rheumatoid Arthritis
What this study did
NCT01197144 · Karolinska Institutet
2010-10 – 2016-11-28 · Arthritis, Rheumatoid, Pain, Fatigue
What this study did
NCT00814866 · Université de Sherbrooke
2008-09 – 2011-03 · Rheumatoid Arthritis
What this study did
NCT00497614 · University Hospital, Tours
2006-05 – 2008-12 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05291039 · Rehab Werida
2022-01-01 – 2023-04-01 · Inflammatory Bowel Diseases
What this study did
NCT04882683 · Shandong Qilu Stem Cells Engineering Co., Ltd.
2021-06-01 – 2022-12-31 · Ulcerative Colitis
What this study did
NCT02634060 · Universitaire Ziekenhuizen KU Leuven
2016-03-31 – 2022-09-05 · Crohn Disease, Colitis, Ulcerative
What this study did
NCT02878083 · Nantes University Hospital
2017-01-11 – 2021-01-01 · ULCERATIVE COLITIS
What this study did
Other / comorbidity
NCT07913750 · Samsung Medical Center
2026-11-15 – 2028-12-31 · Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Panuveitis
What this study did
NCT07491913 · Marmara University
2025-06-15 – 2027-12-15 · Takayasu Arteritis
What this study did
NCT06310837 · Zhongshan Ophthalmic Center, Sun Yat-sen University
2024-03-27 – 2026-07-03 · Uveitis
What this study did
NCT03561649 · University Hospital, Grenoble
2018-06-14 – 2020-05-07 · Spondylitis, Ankylosing
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
Used as active comparator (111)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (55)
Crohn's Disease
NCT03464136 · Janssen Scientific Affairs, LLC
2018-03-29 – 2021-05-21 · Crohn Disease
What this study did
NCT02871635 · Boehringer Ingelheim
2016-09-28 – 2019-05-13 · Crohn Disease
What this study did
NCT01564823 · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012-06 – 2015-01 · Crohn´s Disease
What this study did
Psoriasis
NCT07836283 · University Hospital, Rouen
2026-10-15 – 2030-10-15 · Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis
What this study did
NCT06640517 · Biocad
2024-08-08 – 2028-02 · Plaque Psoriasis
What this study did
NCT06005532 · Mabscale, LLC
2023-10-02 – 2025-12 · Plaque Psoriasis
What this study did
NCT03927352 · Sinocelltech Ltd.
2019-09-05 – 2022-12-31 · Psoriasis
What this study did
NCT02207244 · Janssen Research & Development, LLC
2014-11-03 – 2020-07-01 · Psoriasis
What this study did
NCT02207231 · Janssen Research & Development, LLC
2014-11-26 – 2020-06-17 · Psoriasis
What this study did
NCT03412747 · UCB Biopharma SRL
2018-01-26 – 2020-02-26 · Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
What this study did
NCT03316781 · Shanghai Henlius Biotech
2017-10-27 – 2019-04-22 · Plaque Psoriasis
What this study did
NCT03210259 · Boehringer Ingelheim
2017-07-10 – 2019-04-16 · Psoriasis
What this study did
NCT02762955 · Biocad
2016-12 – 2018-10-15 · Psoriasis
What this study did
NCT02850965 · Boehringer Ingelheim
2016-08-17 – 2018-01-17 · Psoriasis
What this study did
NCT02660580 · Fresenius Kabi SwissBioSim GmbH
2016-02-16 – 2017-12-18 · Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
What this study did
NCT02489227 · Coherus Oncology, Inc.
2015-08 – 2017-03 · Plaque Psoriasis
What this study did
NCT02016105 · Sandoz
2013-12 – 2016-02 · Plaque Type Psoriasis
What this study did
NCT01970488 · Amgen
2013-10-18 – 2015-03-18 · Psoriasis
What this study did
Psoriatic Arthritis
NCT04527380 · Eli Lilly and Company
2021-04-13 – 2029-01 · Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
What this study did
NCT03895203 · UCB Biopharma SRL
2019-04-03 – 2022-07-11 · Psoriatic Arthritis
What this study did
NCT04115748 · Gilead Sciences
2019-12-03 – 2021-05-11 · Psoriatic Arthritis
What this study did
NCT02745080 · Novartis Pharmaceuticals
2017-04-03 – 2019-12-30 · Psoriatic Arthritis
What this study did
NCT01695239 · Eli Lilly and Company
2012-12 – 2017-09 · Psoriasis, Arthritic
What this study did
NCT02714322 · Mylan Inc.
2015-06 – 2017-03 · Psoriasis, Arthritis, Psoriatic
What this study did
NCT01877668 · Pfizer
2014-01-20 – 2015-12-18 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT02332590 · Sanofi
2015-01-28 – 2020-12-29 · Rheumatoid Arthritis
What this study did
NCT03789292 · Celltrion
2018-11-26 – 2020-04-24 · Rheumatoid Arthritis
What this study did
NCT02889796 · Gilead Sciences
2016-08-30 – 2019-06-20 · Rheumatoid Arthritis
What this study did
NCT03052322 · Fresenius Kabi SwissBioSim GmbH
2017-01-31 – 2018-08-27 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT02746380 · LG Life Sciences
2016-04-13 – 2018-02-23 · Arthritis, Rheumatoid
What this study did
NCT02405780 · Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015-06-10 – 2018-01-18 · Arthritis, Rheumatoid
What this study did
NCT02744755 · Sandoz
2016-03-31 – 2017-09-26 · Rheumatoid Arthritis
What this study did
NCT02137226 · Boehringer Ingelheim
2015-01-26 – 2016-10-18 · Arthritis, Rheumatoid
What this study did
NCT02260791 · Fujifilm Kyowa Kirin Biologics Co., Ltd.
2014-12 – 2016-07 · Arthritis, Rheumatoid
What this study did
NCT02167139 · Samsung Bioepis Co., Ltd.
2014-05 – 2015-10 · Rheumatoid Arthritis
What this study did
NCT01710358 · Eli Lilly and Company
2012-10 – 2015-09 · Rheumatoid Arthritis
What this study did
NCT01970475 · Amgen
2013-10 – 2014-11 · Arthritis, Rheumatoid
What this study did
Ulcerative Colitis
NCT02497469 · Takeda
2015-06-29 – 2019-01-18 · Colitis, Ulcerative
What this study did
Other / comorbidity
NCT06333210 · Biocad
2023-12-25 – 2028-02 · Axial Spondyloarthritis
What this study did
NCT04798755 · Hospital San Carlos, Madrid
2022-01-12 – 2025-10-01 · Uveitis
What this study did
Phase 2/3 (1)
Crohn's Disease
NCT03759288 · AstraZeneca
2018-12-07 – 2023-10-18 · Crohn's Disease, IBD
What this study did
Phase 2 (19)
Hidradenitis Suppurativa
NCT07151937 · Almirall, S.A.
2025-11-05 – 2027-11-25 · Hidradenitis Suppurativa
What this study did
NCT05322473 · MoonLake Immunotherapeutics AG
2022-04-25 – 2023-08-30 · Hidradenitis Suppurativa
What this study did
NCT04988308 · Janssen Research & Development, LLC
2021-10-12 – 2022-11-23 · Hidradenitis Suppurativa
What this study did
NCT03248531 · UCB Biopharma SRL
2017-09-22 – 2019-02-21 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT01483599 · Janssen Inc.
2011-11-10 – 2013-08-05 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05640245 · MoonLake Immunotherapeutics AG
2022-12-13 – 2024-01-15 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT07423533 · Changchun GeneScience Pharmaceutical Co., Ltd.
2026-04-30 – 2028-12 · Rheumatoid Arthritis
What this study did
NCT02833350 · Genentech, Inc.
2016-09-09 – 2018-07-02 · Rheumatoid Arthritis
What this study did
NCT01373151 · CSL Behring
2011-06 – 2015-06 · Rheumatoid Arthritis
What this study did
NCT01264770 · AstraZeneca
2011-01 – 2013-08 · Rheumatoid Arthritis
What this study did
NCT02092961 · AstraZeneca
2011-02 – 2013-07 · Rheumatoid Arthritis
What this study did
NCT00595413 · EMD Serono
2007-09 – 2009-10 · Rheumatoid Arthritis
What this study did
NCT00550446 · Pfizer
2007-09 – 2009-01 · Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT06242652 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-03-19 – 2025-06-15 · Ankylosing Spondylitis
What this study did
NCT02929251 · Assistance Publique - Hôpitaux de Paris
2017-06-29 – 2022-01-29 · Uveitis, Biotherapy
What this study did
Phase 1 (20)
Psoriasis
Rheumatoid Arthritis
NCT03254810 · Synermore Biologics Co., Ltd.
2017-09-26 – 2018-07-17 · Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT05108259 · Prestige Biopharma Limited
2022-03-30 – 2027-08 · Healthy Volunteers
What this study did
NCT07181694 · Biocad
2025-03-12 – 2026-02-12 · Healthy Adult Male
What this study did
NCT07147257 · Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
2025-02-12 – 2025-05-29 · Healthy Participants
What this study did
NCT04439929 · Turgut İlaçları A.Ş.
2019-07-17 – 2020-01-16 · Healthy Participants
What this study did
NCT03970824 · Celltrion
2019-05-31 – 2020-01-15 · Healthy
What this study did
NCT03917628 · Sinocelltech Ltd.
2019-05-29 – 2019-11-04 · Healthy
What this study did
NCT03357939 · Shanghai Henlius Biotech
2017-01-12 – 2018-09-15 · Immune System Disorder
What this study did
NCT03579823 · Alvotech Swiss AG
2018-05-21 – 2018-08-24 · Healthy Volunteers
What this study did
NCT02912247 · Innovent Biologics (Suzhou) Co. Ltd.
2016-10-27 – 2017-09-22 · Healthy
What this study did
NCT02927353 · Meiji Seika Pharma Co., Ltd.
2016-08 – 2017-01-17 · Healthy Volunteer
What this study did
NCT05995691 · Amgen
2014-11-24 – 2015-12-04 · Healthy Volunteers
What this study did
NCT02395055 · Biocad
2015-06 – 2015-10 · Healthy
What this study did
NCT02472912 · Mylan Inc.
2014-12 – 2015-06 · Healthy Volunteers
What this study did
NCT02206867 · LG Life Sciences
2014-08 – 2015-02 · Healthy Subjects
What this study did
NCT03014947 · Fresenius Kabi SwissBioSim GmbH
2014-05 – 2014-12 · Healthy Subjects
What this study did
NCT02045979 · Boehringer Ingelheim
2014-01-31 – 2014-06-20 · Healthy
What this study did
NCT01870986 · Pfizer
2013-05 – 2014-02 · Healthy
What this study did
NCT01505491 · Boehringer Ingelheim
2011-12-01 – 2012-07-01 · Healthy
What this study did
Phase 4 (16)
Psoriatic Arthritis
NCT03151551 · Eli Lilly and Company
2017-08-24 – 2019-09-04 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05502731 · Leiden University Medical Center
2022-10 – 2025-10 · Rheumatoid Arthritis
What this study did
NCT06527534 · Universita di Verona
2024-07-15 – 2025-09-15 · Rheumatoid Arthritis
What this study did
NCT04255134 · St George's, University of London
2020-09-07 – 2022-10-26 · Rheumatoid Arthritis
What this study did
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
NCT02092467 · Pfizer
2014-03-14 – 2020-07-22 · Arthritis, Rheumatoid
What this study did
NCT02557100 · Bristol-Myers Squibb
2015-11-19 – 2019-03-28 · Rheumatoid Arthritis
What this study did
NCT01021735 · University of Glasgow
2010-04 – 2015-04 · Rheumatoid Arthritis
What this study did
NCT00808509 · AbbVie (prior sponsor, Abbott)
2009-01 – 2012-09 · Arthritis, Rheumatoid
What this study did
NCT01119859 · Hoffmann-La Roche
2010-05 – 2012-01 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05313620 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2022-04-01 – 2026-06-11 · Ulcerative Colitis, Thromboembolism
What this study did
NCT04131322 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2019-10-10 – 2020-06-08 · Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT07013838 · Chinese SLE Treatment And Research Group
2025-06-15 – 2028-03-31 · Takayasu Arteritis (TAK)
What this study did
NCT02187055 · Pfizer
2014-08 – 2016-12 · Rhematoid Arthritis
What this study did
Appears in other studies (9)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Psoriasis
NCT05073315 · Amgen
2021-10-04 – 2022-12-19 · Plaque Psoriasis
What this study did
Rheumatoid Arthritis
NCT04230213 · Pfizer
2020-01-13 – 2021-06-22 · Rheumatoid Arthritis
What this study did
Phase 2 (1)
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
Phase 4 (5)
Crohn's Disease
NCT03220841 · St Vincent's Hospital Melbourne
2017-10-09 – 2021-09 · Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel
What this study did
NCT00517296 · Vanderbilt University Medical Center
2008-01 – 2015-12 · Crohn Disease, Rectal Fistula
What this study did
Hidradenitis Suppurativa
NCT03221621 · Erasmus Medical Center
2018-07-31 – 2022-07-31 · Hidradenitis Suppurativa
What this study did
Ulcerative Colitis
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT01895764 · University Hospital, Tours
2013-03-20 – 2015-04-27 · Ankylosing Spondylitis
What this study did
Early phase / not applicable (1)
Psoriasis
NCT05503875 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-01-01 – 2027-12-31 · Immunoclassification, Psoriasis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Adalimumab (Humira): this drugApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
BI 3032950Phase 2Monoclonal antibodyTREM-1not yet gradedNo reviewed efficacy summary in this indication
CU104Phase 2Small moleculeEndothelial barrier functionPartial signalNo reviewed efficacy summary in this indication
GarutadustatPhase 2Small moleculePHD1/2not yet gradedNo reviewed efficacy summary in this indication
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
HSK47388Phase 2PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
Live SK08Phase 2Microbiome therapeuticLive biotherapeutic productnot yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Nanosomal TacrolimusPhase 2Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 2Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
OlamkiceptPhase 2Protein / enzyme therapeuticIL-6 transPartial signal
NCT03235752: Clinical response at Week 12: 58.6% olamkicept 600mg vs 34.5% placebo, P=0.032.
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
PALI-2108Phase 2Small moleculePDE4Weak signalFeatured results are safety only in this race
PicankibartPhase 2Monoclonal antibodyIL-23 p19Partial signal
NCT05377580: Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05).
PL8177Phase 2PeptideMC1Rnot yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
SOR102Phase 1Biologic (subtype unspecified)TNF-alpha, IL-23 p19Weak signalFeatured results are safety only in this race
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
BalinatunfibDiscontinuedSmall moleculeTNF-alphanot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 88 furthest-along competitors are listed; 26 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(32 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Humira (adalimumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 2Behcet's UveitisNot yet recruiting
Est. primary completion 2026-11 · NCT05874505 · CT.gov ↗
What to watch
December 2026 (2)
Early phase / not applicablePsoriatic ArthritisNot yet recruiting
Est. primary completion 2026-12-30 · NCT07398651 · CT.gov ↗
What to watch
Phase 4UveitisNot yet recruiting
Est. primary completion 2026-12-31 · NCT05105347 · CT.gov ↗
What to watch
2027 (16)
January 2027 (2)
Phase 1/2Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VIActive not recruiting
Est. primary completion 2027-01 · NCT03153319 · CT.gov ↗
What to watch
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2Tuberculous Meningitis, HIV I InfectionRecruiting
Est. primary completion 2027-06 · NCT05590455 · CT.gov ↗
What to watch
Phase 1Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson SyndromeNot yet recruiting
Est. primary completion 2027-06-01 · NCT06926478 · CT.gov ↗
What to watch
Phase 3Non-Infectious UveitisNot yet recruiting
Est. primary completion 2027-06-01 · NCT06258915 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-28 · NCT06045754 · CT.gov ↗
What to watch
Phase 2Behcet Syndrome, Intestinal TypeRecruiting
Est. primary completion 2027-06-30 · NCT06849908 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Relapsing PolychondritisRecruiting
Est. primary completion 2027-07 · NCT06941376 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-07-30 · NCT05928039 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Ankylosing SpondylitisNot yet recruiting
Est. primary completion 2027-08 · NCT06833112 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Ulcerative ColitisActive not recruiting
Est. primary completion 2027-09 · NCT06257875 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-10-31 · NCT06180382 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2Inflammatory Arthritis, Immune-related Adverse EventRecruiting
Est. primary completion 2027-12 · NCT06037811 · CT.gov ↗
What to watch
Early phase / not applicableTakayasu ArteritisRecruiting
Est. primary completion 2027-12-15 · NCT07491913 · CT.gov ↗
What to watch
Phase 1/2Crohn's DiseaseNot yet recruiting
Est. primary completion 2027-12-31 · NCT07258641 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisActive not recruiting
Est. primary completion 2027-12-31 · NCT06440629 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
April 2028 (2)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2028-04 · NCT07529925 · CT.gov ↗
What to watch
Phase 2Benign Prostatic Hyperplasia (BPH)Recruiting
Est. primary completion 2028-04-01 · NCT06062875 · CT.gov ↗
What to watch
December 2028 (2)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT07510191 · CT.gov ↗
What to watch
Early phase / not applicableNon-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, PanuveitisNot yet recruiting
Est. primary completion 2028-12-31 · NCT07913750 · CT.gov ↗
What to watch
2029 (4)
August 2029 (1)
Phase 2REM Sleep Behavior DisorderRecruiting
Est. primary completion 2029-08-01 · NCT06996652 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Folliculitis Decalvans (FD)Not yet recruiting
Est. primary completion 2029-11-01 · NCT07268534 · CT.gov ↗
What to watch
Phase 4Juvenile Idiopathic Arthritis (JIA)Not yet recruiting
Est. primary completion 2029-11-11 · NCT07904780 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Uveitis, Chronic DiseaseNot yet recruiting
Est. primary completion 2029-12 · NCT06390436 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 1/2Type 1 Diabetes, New OnsetRecruiting
Est. primary completion 2030-04-15 · NCT07061574 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, AnteriorNot yet recruiting
Est. primary completion 2030-05 · NCT07699107 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2Major Depressive Disorder (MDD)Recruiting
Est. primary completion 2031-07 · NCT07845604 · CT.gov ↗
What to watch

See the full readout calendar ↗